FDA approves Allergan’s Restasis Multidose

SILVER SPRING, Md. — The Food and Drug Administration has approved Allergan’s Restasis Multidose, (cyclosporine ophthalmic emulsion 0.05%), the company announced Friday. The approval brings a new delivery system for the company’s eye drops, which are approved to help patients with chronic dry eye produce more of their own tears. 

 

“Restasis Multidose exemplifies Allergan's commitment to innovation and customer responsiveness,” Allergan’s chief R&D officer, David Nicholson, Chief R&D Officer at Allergan. “Through our Open Science model, we drive to deliver advancements in highly engineered developments, such as the new multi-dose bottle.”

 

Restasis Multidose has a unidirectional valve and air filter technology that the company says eliminates the need for a preservative, and the bottle uses less plastic than a package of single-use vials. It will be available for the same price as the single-dose vials.